Overview

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .

Phase:

Phase 3

Details

Lead Sponsor:

Radius Pharmaceuticals, Inc.

Treatments:

Anastrozole
Fulvestrant